We herein demonstrate that STAT6 plays an important role in the induction of not only acute contact hypersensitivity (CHS), but also chronic CHS in a mouse model using STAT6-deficient (STAT6 À/À ) mice. We, therefore, determine whether synthetic double-stranded DNA with a high affinity for STAT6 can be introduced in vivo as a decoy cis element to bind the transcriptional factor and block the induction of not only acute CHS but also chronic CHS. Treatment by the transfection of STAT6 decoy oligodeoxynucleotides (ODN), after the induction of 2,4,6-trinitrochlorobenzene or other haptens had a significant inhibitory effect on the induction of both acute CHS and chronic CHS. We thus examined the mechanism of the in vivo effect of the transfection of STAT6 decoy ODN in both acute and chronic CHS. In the histological analysis, the infiltration of eosinophils and degranulated mast cells, and the production of IL-4, IL-6 and eotaxin, but not IFN-g in the extracts from challenged skin significantly decreased by the transfection of STAT6 decoy ODN. We herein report the first successful in vivo transfer of STAT6 decoy ODN to inhibit acute and chronic CHS, thus providing a new therapeutic strategy not only for the treatment of CHS but also for atopic dermatitis.
Introduction
Contact hypersensitivity (CHS) responses are mediated by T cells following the epicutaneous application of chemically reactive compounds (haptens) to the skin. CHS is thought to be associated with the activation of T cells of Th (T helper) 1 type. However, the role of Th2 cells in CHS is still not clear. Interleukin-4 (IL-4)/IL-10 secreting CD4+ T cells (Th2) have been demonstrated to negatively regulate the CHS response. 1 Steinbrink et al 2 suggested that CD8+ T cells producing IL-4, -5 and -10 play a downregulatory role. A negative regulatory effect of IL-4 on the CHS responses to trinitrochloronbenzene (TNCB) has been also reported by Guatam et al 3 and Asada et al. 4 These authors observed that IL-4 inhibited the efferent phase of CHS but not the afferent phase. 3, 4 In contrast to these reports, IL-4 has been demonstrated to be an essential cytokine during the elicitation phase of CHS by several groups. [5] [6] [7] In line with these reports, the CHS response has been reported to be diminished in IL-4-deficient mice at the late phase of the elicitation reaction. 8 We have recently established STAT6-deficient (STAT6 À/À ) mice 9 and demonstrated that STAT6 plays an essential role in the induction of CHS. 10 We also recently reported that not only Th2 cytokines, but also mast cells and IgE are important in the induction of CHS. 11, 12 Furthermore, Kitagaki et al 13, 14 demonstrated that the repeated elicitation of CHS (chronic CHS) induces a shift in the cutaneous cytokines milieu from a Th1 to a Th2 profile. They demonstrated that an important function of Th2 cells and mast cells in chronic CHS may be to minimize the tissue-damaging effects of Th1 cells by producing Th2 cytokines. 13, 14 They concluded that this chronic CHS mouse model could thus play a beneficial role in investigating the pathogenesis of such chronic allergic diseases as atopic dermatitis. 13, 14 We, therefore, focused our attention on the role of STAT6 in the pathogenesis of both acute and chronic CHS using STAT6 À/À mice. Recently, a decoy strategy has been developed and considered a useful tool as a new class of antigene strategy. 15, 16 The transfection of double-stranded oligodeoxynucleotides (ODN) as a decoy corresponding to the cis sequence results in the attenuation of the authenic cis-trans interaction, leading to the removal of transfactors from the endogeneous cis-element, with a subsequent modulation of gene expression. 15, 16 Therefore, this decoy approach enables us to treat diseases by modulating endogenous transcriptional regulation. [17] [18] [19] [20] [21] Recently, several skin diseases have been reported to improve after decoy ODN therapy. 22, 23 We, therefore, hypothesized that the acute and chronic CHS response in contact dermatitis or eczema might also improve by the transfection of STAT6 decoy ODN. If the expression of Th2 cytokine is involved in the development of CHS, then the most important step in the process of CHS might be suppressed by STAT6 decoy ODN in vivo. These studies demonstrated that the transfection of STAT6 decoy ODN during the induction phase of CHS resulted in a significant improvement of CHS. Since the role of STAT6 is limited in IL-4 signaling, the side effects by STAT6 decoy ODN would thus be expected to be slight. There are few therapies for severe eczema, contact dermatitis and atopic dermatitis except for systemic glucocorticoids or immunesuppresants, which have several side effects. The application of STAT6 decoy ODN appears to provide a novel therapeutic effect without any significant local or adverse effects.
Results

Diminished CHS response to TNCB in STAT6
À/À mice
Our initial experiments were conducted to determine whether or not the repeated epicutaneous application of TNCB could result in a shift to an earlier point in the time course of the CHS response as had been demonstrated in previous reports 13 ( Figure 1a,b) . As shown in Figure 1a and b, repeated TNCB application induced a shift in the pattern of the CHS response. To further evaluate the capacity of STAT6 À/À mice to develop a CHS reaction, we compared the ear-swelling response of STAT6 À/À mice with WT (C57BL/6) mice in acute and chronic TNCB-induced CHS. The peak response of ear swelling was detected at 4 and 24 h after the challenge in acute CHS to TNCB in WT mice, whereas, a peak response was observed at 24 h after challenge in STAT6 À/À mice ( Figure 1a ). On the other hand, the peak response in ear swelling was detected only at 6 h after challenge in chronic CHS to TNCB in both WT mice and STAT6 À/À mice ( Figure 1b ). As shown in Figure 1a , b, in comparison with STAT6 À/À mice, 61% suppression of ear swelling was observed in acute CHS (a) and 59% suppression was observed in chronic CHS (b).
Histopathology of TNCB-induced CHS response in WT and STAT6
We performed a histological analysis of the challenged skin in STAT6 À/À mice and WT mice. As shown in Figure  1c , strong edema was observed in the challenged skin of WT mice demonstrating an acute and chronic CHS response, however, edematous change was weak in the STAT6 À/À mice. An inflammatory response with a strong infiltration of eosinophils and mononuclear cells was observed in WT mice after challenge in acute and chronic CHS. In contrast, only a mild inflammatory response with a diminished infiltration of mononuclear cells and eosinophils was observed in the challenged skin of both acute and chronic CHS in STAT6 À/À mice (Figure 1c) .
In vivo transfection of fluorescence isothiocyanate-labeled ODN into the skin
In order to evaluate the efficacy and localization of the delivered STAT6 decoy ODN with HVJ-E, we introduced fluorescence isothionated-labeled decoy ODN against STAT6 with HVJ-E into the mouse skin by means of a subcutaneous injection with HVJ-E. It is noteworthy that FITC-labeled STAT6 decoy ODN was more strongly expressed in the cytoplasm of dermal cells than the control skins transfected into an empty envelope (Figure 2a, b) .
In vivo transfection of STAT6 decoy ODN
To confirm that STAT6 decoy ODN with HVJ-E inhibits the binding of STAT6, nuclear extracts from ear tissues injected with STAT6 decoy ODN were obtained, and a gel-shift analysis was performed with a radiolabeled STAT5/6 probe. Figure 2c showed that the challenge with TNCB resulted in the activation of STAT6 (line 2). The increased STAT6 binding was abolished by excess amounts of cold STAT6 probe (line 5). Furthermore, the in vivo transfection of STAT6 decoy ODN with HVJ-E, but not scrambled decoy ODN with HVJ-E (line 4) markedly inhibited the increased STAT6 binding (line 3). These data indicate the interference of STAT6 activation by in vivo transfection of STAT6 decoy ODN.
Inhibition of both the acute and chronic CHS to TNCB, DNFB, and Oxa by the transfection of STAT6 decoy ODN
To determine the inhibition of decoy ODN against STAT6 in terms of the response of CHS, the ear-swelling response challenged with TNCB was examined with or without the administration of STAT6 decoy ODN or scrambled decoy ODN. STAT6 decoy ODN inhibited both the acute (Figure 3a ) and chronic (Figure 3b ) CHS responses significantly. % Inhibition of acute CHS or chronic CHS was 62 or 63%, respectively. To optimize the effective dose of STAT6 decoy ODN, the ear-swelling responses were examined by the injection of several doses of STAT6 decoy ODN with 0.2, 2, and 20 mM. As shown in Figure 3c , 20 mM, but not 0.2 mM, 2 mM of STAT6 decoy ODN effectively inhibited the CHS response.
To examine whether or not similar effects were observed in CHS to other haptens, we induced CHS to DNFB (Figure 3d , e), Oxa (Figure 3f, g ). STAT6 decoy ODN significantly inhibited both the acute CHS to DNFB (Figure 3d ) and chronic (Figure 3e, g ) CHS response to DNFB, 67 or 62%, respectively. STAT6 decoy ODN also inhibited both acute CHS to Oxa (Figure 3f ) and chronic CHS to Oxa (Figure 3 g ).
Histopathology of the acute and chronic CHS response in mice treated with or without STAT6 decoy ODN
We performed a histopathological analysis of TNCBinduced skin injected with or without STAT6 decoy ODN or scrambled decoy ODN. As shown in Figure 4a , marked dermal edema was detected in the challenged skin of either nontransfected (positive control) or scrambled decoy ODN-transfected mice in both acute and chronic CHS to TNCB, however, edematous change was weak in the mice transfected with STAT6 decoy ODN. An inflammatory response with a strong cellular infiltration was observed in nontransfected or scrambled decoy ODN-transfected mice at 24 h after challenge in ) and C57BL/6 (WT) mice (': TNCB-WT) were sensitized with 5% TNCB solution on shaved abdominal skin and challenged 12 times with 1% TNCB solution every other day on ear lobes from day 4 to 26. The maximal ear swelling was detected at 6 h after 12th application. The data presented are the mean values7s.d. of at least five mice per group. *Po0.01, significant compared with the results of WT mice. (c) Histopathological findings of the acute/ chronic CHS induced in WT or STAT6 À/À mice stained with Giemsa solution. At the last challenge, each ear lobe was challenged with vehicle or TNCB. An extremely large degree of edema was detected in the TNCB-challenged skin in the WT mice, but edematous change was weak in the STAT6 À/À mice in both acute and chronic CHS. A strong inflammatory cellular infiltration was observed in the dermis of the positive control WT mice in acute and chronic CHS. 
Discussion
CHS is thought to be dependent on Th1 cells 1,2 although IL-4 has also been demonstrated to be involved in the response of CHS. [5] [6] [7] It has also been reported that Th2 cells in mouse skin can induce a cellular inflammatory response with faster kinetics. 24 To clarify this question, we recently established STAT6-deficient mice and concluded that STAT6 plays a central role in the induction of CHS. 10 Furthermore, recent in vivo studies have demonstrated that many immune responses start predominantly as a Th1 to a Th2 response. 25, 26 In line with these studies, the CHS response has also been demonstrated to start predominantly as a Th1 to a Th2 response. We, herein, examined the role of STAT6 in the induction of a response by repeated elicitation of CHS. We confirmed that the repeated elicitation of CHS to TNCB induced a shift from the Th1 to a Th2 response in wt mice, however, in comparison with the wt control mice, the ear-swelling response in STAT6 À/À mice significantly decreased at 6 h after the last elicitation. This reduction of the peak response induced by the repeated challenge was also observed at 1-6 h in STAT6 À/À mice sensitized with Oxa or DNFB as the contact allergen. These data indicated that STAT6 plays a crucial role in the induction of not only the single elicitation of CHS (acute CHS), but also the repeated elicitation of CHS (chronic CHS).
These results of the response induced by a single and repeated elicitation of CHS in STAT6
À/À mice suggested that the blocking of the STAT6 signaling can be a therapeutic approach for CHS. We thus examined whether in vivo treatment with the transfection of STAT6 decoy ODN with HVJ-envelope (E) after the sensitization can effectively inhibit STAT6 binding to the nucleus and the response induced by the single or repeated application to TNCB. The subcutaneous injection of STAT6 decoy ODN with HVJ-E after sensitization exhibited a significant inhibitory effect on both STAT6 binding to nucleus and the late-phase response in line with Kaneda's report. 27 A histopathological analysis revealed a tremendous reduction in both the infiltration of eosinophils, mast cells, and especially mast cell degradation in single or repeated challenged skin in STAT6 decoy ODN-transfected mice. STAT6 signaling is essential for the hapten-induced increase in Th2 cytokines production in vivo. The ELISA technique showed the production of protein of the Th2 cytokines (ie, IL-4), IL-6 and eotaxin to decrease in STAT6 decoy ODN-transfected mice, but not in scrambled decoy ODN-transfected mice in both acute and chronic CHS, whereas the serum IgE level was not inhibited by STAT6 decoy ODN. It was noteworthy that STAT6 decoy ODN strongly inhibited the IL-6 production in chronic CHS. These data indicated that the latephase reaction induced by mast cells may play a major role in the pathogenesis of chronic CHS in line with the previous reports, 13, 14 since IL-6 production from mast cells is dependent on STAT6 signaling in the late-phase allergic responses. 28 Recently, eotaxin has been reported to be induced by fibroblast stimulated with IL-4 through STAT6 pathway. 29, 30 Eotaxin induced by fibroblasts stimulated with IL-4 may thus play a major role in the chemotaxis of eosinophils. However, since STAT6 also affects the cytokine response of other inflammatory cells, such as macrophages or T cells, the significant contribution of cells other than mast cells in late-phase allergic response might be inhibited by STAT6 decoy ODN. These data indicated that the STAT6 signal is essential in the production of Th2 cytokine, chemokine for eosinophils and the activation of mast cells.
In summary, (1) STAT6 is essential in the induction of both acute and chronic CHS. (2) STAT6 mediates the ear-swelling response induced by single and repeated (5) The inhibition of the response in acute and chronic CHS by STAT6 decoy ODN delivered by the subcutaneous administration was observed. (6) The decrease in the number of eosinophils, mononuclear cells, mast cells, and degranulated mast cells seemed to be associated with the decreased production of IL-4 and IL-6. In addition, this study demonstrated that the transcriptional factor, STAT6, is one of the key regulators promoting IgE-mediated late-phase reaction. Although a number of important issues, such as safety and side effects, have not yet been addressed in this study, the decoy strategy against STAT6 may be useful as a new therapeutic modality as gene therapy against contact dermatitis and atopic dermatitis. Since STAT6 has been postulated to play an important role in the pathogenesis of numerous diseases, for example, atopic asthma and allergic rhinitis, the development of STAT6 decoy strategy may also provide useful therapeutic tool for treating these diseases.
Materials and methods
Animals
C57BL/6 mice with a targeted disruption of the gene encoding STAT6 (STAT6
) were generated in the Department of Biochemistry at the Hyogo College of Medicine as previously reported, 9 and age-matched wild-type (WT) littermate controls (C57BL/6 and BALB/c mice) were purchased from Oriental Yeast Co Ltd (Shizuoka, Japan). All animals were maintained in specific pathogen-free facilities at the Tokyo Medical and Dental University Postgraduate School animal facilities in accordance with institutional guidelines, and all mice had free access to a commercial diet and water. They were used at 8-10 weeks of age. Each experimental group consisted of at least five mice.
Contact sensitizing reagents
The following reagents were obtained from commercial sources; 2,4,6-trinitro-1-chlorobenzene (TNCB) and 2,4-dinitrofluorobenzene (DNFB) from Nacalai Tesque, Inc. Immunization for induction of CHS to TNCB, DNFB, and Oxa All mice were sensitized by two daily consecutive topical epicutaneous applications of 50 ml of 5% TNCB solutions, 0.5% DNFB solutions, and 3% Oxa solutions in acetone in olive oil (4:1) to the shaved abdominal skin, as described previously. 10 
Elicitation and quantitation
At 3 days after the last abdominal application, the mice were challenged by applying 20 ml of hapten solution (1% TNCB, 0.2% DNFB, or 0.5% Oxa in olive oil in acetone (4:1)) or vehicle (without TNCB, DNFB, or Oxa) on both sides of the ear lobe for the first elicitation (day 4). These groups of mice were categorized to acute CHS. Thereafter, in order to produce the chronic CHS model, the same solutions were applied 12 times to the same skin site every other day. The thickness of the ear was then measured with an engineer's micrometer (peacock; OZAKI MFG. Co., Ltd., Tokyo) at 1, 4, 6, 12, 24, 36, 48 , and 72 h after challenge. The negative control mice were treated in the same fashion without hapten at only last challenge.
The percent suppression was calculated according to the formula: The STAT6 decoy ODN is a double-stranded phosphorothioate 28-mer that exhibits a high sequencespecific binding affinity to the transcription factor STAT6. Gene therapy for contact hypersensitivity K Sumi et al Figure 5 Cytokine levels in the skin tissue extract and serum IgE level by ELISA assay. The cytokine levels in the TNCB-challenged skin supernatants of IL-4 (a, b), IFN-g (c, d), eotaxin (e, f), and IL-6 (g, h) in both acute (a, c, e, g) and chronic (b, d, f, h) CHS were presented. In addition, the production of serum IgE was not affected by STAT6 decoy ODN in both acute (i) and chronic CHS (j). These data represent the mean7s.d. for groups of four mice and are representative of three independent experiments. *Po0.01, **Po0.05 significantly compared with the cytokine levels of the positive control or scrambled decoy ODN with HVJ-E. These results represent the findings of three independent experiments. N: negative control, P: positive control, S6: STAT6 decoy ODN, Sc: scrambled decoy ODN.
Gene therapy for contact hypersensitivity K Sumi et al Synthetic ODNs were dissolved in sterile Tris-EDTA buffer (10 mM Tris, 1 mM EDTA pH 8.0), purified by high-performance liquid chromatography and quantitated by spectrophotometry. Each pair of single-stranded ODN was annealed for 3 h, during which time, the temperature was reduced from 90 to 251C. These decoy ODNs were then stored at À201C until use.
Preparation of the HVJ-E vector
HVJ (also known as Sendai virus) was amplified as described previously. 27 The virus was inactivated by b-propiolactone (0.0075-0.001%) treatment or by UV irradiation. In both cases, the virus preparation lost the ability to replicate. The aliquots of the virus (3 Â 10 10 particles/1.5 ml tube) were centrifuged (18 500 g, 15 min) at 41C, and the viral pellet was stored at À201C.
27
The inactivated virus suspension (10 000 haemagglutinating activity units (HAU)) was mixed with STAT6 decoy OND or scrambled decoy ODN (800 mg of DNA), 8 ml of 3% Triton/TE and balanced salt solution (BSS; 10 nM Tris-HCl (pH 7.5), 137 mM NaCl and 5.4 mM KCl)) to yield a final volume of 100 ml. The mixture was centrifuged at 18 500 g for 15 min at 41C. After the pellet was washed with 1 ml of human tubal fluid (HTF) medium (Nippon Medical & Chemical Instrument Co. Ltd, Osaka, Japan) to remove the detergent and unincorporated DNA, the envelope vector was suspended in 250 ml of HTF medium. Approximately 15-20% of DNA was incorporated into the vector. The HVJ-E vector was stored at 41C until use. HVJ-E vector is also commercially available from Ishihara Sangyo Co. Ltd (Osaka, Japan).
In vivo transfer of ODN and FITC-labeled ODN
FITC was used to label the 5 0 -ends of STAT6 decoy ODN and Scrambled decoy ODN. These ODNs were injected to ear lobe subcutaneously at one day before the last challenge; in a word, in the case of acute CHS, ODNs were injected on day 4, and, in that of chronic CHS, on day 26. After transfection, the mice were killed, and ears were removed. Next, the sections were examined by fluorescent microscopy.
Electrophoretic mobility-shift assays (EMSA)
As previously described, 32 the mouse ear lobe was homogenized in 500 ml of ice-cold homogenization buffer (10 mM HEPES, pH 7.5, 0.5 M sucrose, 0.5 mM spermidine, 0.15 mM spermine, 5 mM EDTA, 0.25 M EGTA, 7 mM b-mercaptoethanol, and 1 mM phenylmethylsulfonyl fluoride) containing 0.1% Nonidet P-40. The samples were then centrifuged at 14 000 rpm for 30 min at 41C, and the pellet nucleus was washed twice with ice-cold buffer containing 0.35 M sucrose.
After washing, the nucleus was extracted with 500 ml of ice-cold homogenization buffer containing 0.05 M NaCl and 10% glycerol for 15 min at 41C, followed by a further extraction with homogenization buffer containing 0.3 M NaCl and 10% glycerol for 1 h at 41C. After centrifugation at 15 000 rpm for 30 min at 41C, the pellet was dissolved with homogenization buffer containing 0.35 M sucrose to obtain the concentration of DNA at 1 mg/ml. Then, the samples were stored in aliquots at À801C.
After preincubation with 2 mg poly(dI-dC) as nonspecific competiter DNA, 2 ml sample of the crude nuclear extract were incubated in a binding buffer containing 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 20 mg/ml aprotinin, and 10 ml/ml leupeptin with approximately 10 000 cpm of annealed 32 P-labeled probe for 30 min at room temperature. The sequence of the probe for STAT5/6 was 5 0 -GTA TTT CCC AGA AAA GGA AC-3 0 (Santa Cruz Biotechnology Inc.). The sequence of the mutant STAT6 probe was 5 0 -GTA TTT CGG TTA AAA GGA AC-3 0 . The binding reaction mixtures were separated from free oligonucleotide probes by electrophoresis on a native 5% (w/v) gel as described. 33 The reaction mixture was subjected to electrophoresis as previously described and thereafter the gels were dried and autoradiographed.
Histological examination
The ear skin specimens were excised and fixed in 10% formalin, and then were processed and stained with hematoxylin and eosin (HE), or May-Grunwald-Giemsa. The number of mononuclear cells, mast cells, and eosinophils infiltrating into the dermis was evaluated under light microscopy. The section was examined at a magnification of Â 400. At least 20 fields were examined for each lobe. The number of cells was counted and expressed as the number of cells per mm 2 .
Quantification of cytokine levels in skin tissue extracts
Samples of the ear extracts for ELISA were prepared as described by Ferguson et al. 34 Briefly, at 24 h after application of TNCB (acute CHS) and at 4 h after application of TNCB (chronic CHS), the ears were excised and immediately homogenized with 1 cm 3 of 0.1% Tween-20 in PBS. The samples were quickly frozen in liquid nitrogen, thawed in a 371C water bath, sonicated for 15 s, and centrifuged for 5 min at 13 000 g, and supernatants were used as samples for ELISA. The supernatants were stored at À801C. First, we measured the total protein levels in the supernatants with Protein Assay s (BIO-RAD, Hercules, CA, USA) according to the manufacturer's instructions. Second, the ELISA assays for IL-4, IFN-g, IL-6, and eotaxin were conducted using ELISA kits (IL-4, IFN-g, IL-6: Pierce Endogen, Rockford, IL, USA; eotaxin: TECHNE Corporation, Minneapolis, MN, USA) according to the manufacturer's instructions. The ratios of these cytokine levels in total protein level were examined.
Statistical analysis
The experimental data are expressed as the mean7s.d. (standard deviation) and shown in the figures as the mean+s.d. for clarity. The statistical analysis was performed using Student's t-test.
